129 related articles for article (PubMed ID: 35304238)
21. A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy.
Liu SQ; Grantham A; Landry C; Granda B; Chopra R; Chakravarthy S; Deutsch S; Vogel M; Russo K; Seiss K; Tschantz WR; Rejtar T; Ruddy DA; Hu T; Aardalen K; Wagner JP; Dranoff G; D'Alessio JA
Cancer Immunol Res; 2021 Jan; 9(1):34-49. PubMed ID: 33177106
[TBL] [Abstract][Full Text] [Related]
22. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
23. Target-independent Immune-cell Activation by Aggregates of T Cell-redirecting Bispecific Antibodies.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2023 Sep; 112(9):2419-2426. PubMed ID: 37392901
[TBL] [Abstract][Full Text] [Related]
24. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
25. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
26. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
27. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a Novel Bispecific Antibody That Activates T Cells
Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
[TBL] [Abstract][Full Text] [Related]
29. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
30. Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.
Meng W; Tang A; Ye X; Gui X; Li L; Fan X; Schultz RD; Freed DC; Ha S; Wang D; Zhang N; Fu TM; An Z
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038280
[TBL] [Abstract][Full Text] [Related]
31. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
Lipe BC; Renaud T
J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
[TBL] [Abstract][Full Text] [Related]
32. Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.
Kamperschroer C; Guffroy M; Shen A; Dokmanovich M; Stubbs M; O'Donnell LM
J Immunother; 2024 Jun; 47(5):160-171. PubMed ID: 38562119
[TBL] [Abstract][Full Text] [Related]
33. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines.
Wang D; Zhang L; Wang B; Zhao L; Deng L; Xu W; Huang H
Protein Expr Purif; 2023 May; 205():106242. PubMed ID: 36746324
[TBL] [Abstract][Full Text] [Related]
34. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics.
Kamperschroer C; Shenton J; Lebrec H; Leighton JK; Moore PA; Thomas O
J Immunotoxicol; 2020 Dec; 17(1):67-85. PubMed ID: 32100588
[TBL] [Abstract][Full Text] [Related]
35. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
36. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
37. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.
Leclercq G; Servera LA; Danilin S; Challier J; Steinhoff N; Bossen C; Odermatt A; Nicolini V; Umaña P; Klein C; Bacac M; Giusti AM; Schneider A; Haegel H
Oncoimmunology; 2022; 11(1):2039432. PubMed ID: 35186442
[TBL] [Abstract][Full Text] [Related]
38. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
39. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
40. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
